Undisclosed Placental Protein Program
Autoimmune disorders & Solid organ transplant rejection
Key Facts
About Mitera Biosciences
Mitera Biosciences is a private, preclinical biotech founded in 2020 and headquartered in Bellevue, Washington (with operations in San Diego), focused on immune tolerance. The company is developing therapeutic candidates derived from a natural human placental/thymic protein, with a novel mechanism designed to simultaneously impair effector T cells, proliferate regulatory T cells, and downregulate B cell activation. With intellectual property licensed from Cedars-Sinai Medical Center and recent seed funding, Mitera is advancing its lead program toward clinical development for transplant rejection and autoimmune disorders, targeting a significant unmet need for non-toxic immunosuppression.
View full company profile